April 11th 2019
Immuron seeking FDA approval for travelers’ diarrhea drug candidate
November 19th 2018
Immuron appoints a new CEO to lead it into the future
September 5th 2018
Immuron’s Travelan® protects against Shigella in primates
July 25th 2018
Immuron generates strong Travelan sales growth
July 16th 2018
US Defense finishes latest research on Immuron’s Travelan®
March 14th 2018
Immuron Announces A$5.1M Private Placement to U.S. Fund
March 8th 2018
Results in: IMC’s lead drug reduces major factor in liver inflammation
February 16th 2018
Big spike in sales growth for IMC’s Travelan® product
October 25th 2017
Broker sees substantial upside in Immuron with catalysts imminent
August 28th 2017
Immuron takes another step towards addressing US$10 billion CDI market
July 11th 2017
Immuron gets go-ahead for finalisation of IMM-124E trials
June 2nd 2017
Sales of Immuron’s Travelan up 13% as it considers geographic expansion
May 17th 2017
Immuron expands collaboration with US Department of Defence
May 10th 2017
Immuron completes manufacturing trial supplies of IMM-529
April 18th 2017
Immuron completes first stage of colitis preclinical program
April 7th 2017
Clinical studies could provide market moving news for Immuron in 2017
March 30th 2017
Immuron targets the gut not the liver
Connect with us
